RT Journal Article
T1 Hyperkalaemia management and related costs in chronic kidney disease patients with comorbidities in Spain.
A1 Olry de Labry Lima, Antonio
A1 Díaz Castro, Óscar
A1 Romero-Requena, Jorge M
A1 García Díaz-Guerra, M de Los Reyes
A1 Arroyo Pineda, Virginia
A1 de la Hija Díaz, M Belén
A1 Ascanio, Meritxell
A1 Darbà, Josep
A1 Cruzado, Josep M
K1 chronic kidney disease
K1 diabetes
K1 heart failure
K1 hyperkalaemia
K1 renin–angiotensin–aldosterone system inhibitors
AB Hyperkalaemia (HK) is a common electrolyte disorder in patients with chronic kidney disease (CKD) and/or treated with renin-angiotensin-aldosterone system inhibitors (RAASis). The aim of this study is to determine the severity, current management and cost of chronic HK. We performed a retrospective cohort study of patients with chronic HK and CKD, heart failure or diabetes mellitus between 2011 and 2018. The study follow-up was 36 months. A total of 1499 patients with chronic HK were analysed: 66.2% presented with mild HK, 23.4% with moderate HK and 10.4% with severe HK. The severity was associated with CKD stage. Most patients (70.4%) were on RAASi therapies, which were frequently discontinued (discontinuation rate was 39.8, 49.8 and 51.8% in mild, moderate and severe HK, respectively). This RAASi discontinuation was similar with or without resin prescription. Overall, ion-exchange resins were prescribed to 42.5% of patients with HK and prescriptions were related to the severity of HK, being 90% for severe HK. Adherence to resin treatment was very low (36.8% in the first year and 17.5% in the third year) and potassium remained elevated in most patients with severe HK. The annual healthcare cost per patient with HK was €5929, reaching €12 705 in severe HK. Costs related to HK represent 31.9% of the annual cost per HK patient and 58.8% of the specialized care cost. HK was usually managed by RAASi discontinuation and ion-exchange resin treatment. Most patients with HK were non-adherent to resins and those with severe HK remained with high potassium levels, despite bearing elevated healthcare expenditures.
SN 2048-8505
YR 2021
FD 2021-04-07
LK https://hdl.handle.net/10668/24710
UL https://hdl.handle.net/10668/24710
LA en
DS RISalud
RD Apr 5, 2025